(VIANEWS) – Corcept Therapeutics Incorporated (CORT), Ameresco (AMRC), Synopsys (SNPS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Corcept Therapeutics Incorporated (CORT)
35.4% sales growth and 21.91% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $1.05.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 28.73. Meaning, the purchaser of the share is investing $28.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.91%.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 1374270 which is 29.26% above its average volume of 1063150.
Moving Average
Corcept Therapeutics Incorporated’s value is way higher than its 50-day moving average of $25.55 and way higher than its 200-day moving average of $26.64.
2. Ameresco (AMRC)
32.9% sales growth and 5.86% return on equity
Ameresco, Inc. provides comprehensive energy services for businesses and organizations in North America and Europe. It offers energy efficiency, infrastructure upgrades, energy security and resilience, asset sustainability, and renewable energy solutions. The company operates through U.S. Regions, U.S. Federal, Canada, and Non-Solar Distributed Generation segments. It designs, develops, engineers, and installs projects that reduce the energy, as well as operations and maintenance costs of customers' facilities. The company's projects primarily include various measures customized for the facility and designed to enhance the efficiency of building systems, such as heating, ventilation, cooling, and lighting systems. It also offers renewable energy products and services, such as the construction of small-scale plants for customers that produce electricity, gas, heat, or cooling from renewable sources of energy; and sells electricity and processed renewable gas fuel, heat, or cooling. In addition, the company provides integrated- photovoltaic (PV) and consulting, and enterprise energy management services; sells solar PV energy products and systems; and owns and operates a wind power project located in County Kerry, Ireland. It serves federal, state, and local governments, as well as healthcare and educational institutions, housing authorities, and commercial and industrial customers. As of December 31, 2019, the company owned and operated 99 small-scale renewable energy plants and solar PV installations. Ameresco, Inc. was founded in 2000 and is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Ameresco has a trailing twelve months EPS of $1.09.
PE Ratio
Ameresco has a trailing twelve months price to earnings ratio of 31.16. Meaning, the purchaser of the share is investing $31.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.86%.
Yearly Top and Bottom Value
Ameresco’s stock is valued at $33.96 at 01:22 EST, way below its 52-week high of $63.19 and way higher than its 52-week low of $17.55.
3. Synopsys (SNPS)
8.6% sales growth and 21.58% return on equity
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $9.04.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 61.63. Meaning, the purchaser of the share is investing $61.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.58%.
Moving Average
Synopsys’s value is above its 50-day moving average of $556.77 and higher than its 200-day moving average of $526.64.
Sales Growth
Synopsys’s sales growth for the next quarter is 8.6%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 6.31B for the twelve trailing months.
Yearly Top and Bottom Value
Synopsys’s stock is valued at $557.16 at 01:22 EST, way under its 52-week high of $629.38 and way higher than its 52-week low of $416.87.
4. Merit Medical Systems (MMSI)
6.7% sales growth and 8.45% return on equity
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Earnings Per Share
As for profitability, Merit Medical Systems has a trailing twelve months EPS of $1.74.
PE Ratio
Merit Medical Systems has a trailing twelve months price to earnings ratio of 47.58. Meaning, the purchaser of the share is investing $47.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.45%.
